Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Momenta and Sandoz fail on US enoxaparin

Executive Summary

Momenta and Sandoz face the prospect of paying treble damages to Amphastar over allegations the two firms “restricted trade and prevented competition in the manufacture and sale of generic enoxaparin” in the US, after a district judge denied Momenta’s bid to dismiss the US-based specialty company’s antitrust lawsuit.

You may also be interested in...



Amphastar Will Receive $59.9m In Momenta/Sandoz Settlement

The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement

The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

Sandoz, Momenta And Amphastar Settle US Enoxaparin Litigation

Long-running US patent and antitrust litigation between Sandoz, Momenta and Amphastar over enoxaparin has been brought to an end after the parties agreed a settlement deal.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB000639

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel